At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 642 enrolled

Drug / intervention

Citalopram +1 moredrug

Likely dose

Citalopram 40 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01937182

NCT01937182Phase 2Completed

Compare CT.gov

The Efficacy of Citalopram Treatment in Acute Stroke

University of Aarhus·interventional·Posted Sep 9, 2013·Updated Feb 24, 2017

In Brief

A Phase 2 clinical trial evaluating Citalopram and Placebo for Stroke, Ischemic. Completed, enrolled 642 participants across 3 sites.

Detailed Summary

We wish to conduct a prospective, randomized, double blind, placebo controlled multi center study of the combined neuroprotective and antithrombotic effects of SSRI treatment after stroke. Hypotheses: SSRI treatment commenced in the acute phase of stroke (day 0-7) protects against new thromboembolic events and leads to better rehabilitation. 600 stroke patients will be randomized in a 1:1 ratio. The treatment and follow up period is 6 months. During these 6 months there will be 2 clinical follow up visits, one telephone control and one visit to evaluate compliance regarding medication.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsStroke, Ischemic

CountriesDenmark

CollaboratorsDanish Council for Independent Research, The Danish Regions Medicine Foundation

Timeline

Phase 2CompletedFinished

2014201520162017201820192020202120222023202420252026

Enrollment StartSep 2013

First PostedSep 2013

Primary CompletionDec 2016

TodayJul 2026

First PostedSep 9, 2013

Enrollment StartSep 1, 2013

Primary CompletionDec 19, 2016

TodayJul 2, 2026

Enrollment to primary: 3.3 yearsPosted 12.8 years ago

Interventions

Citalopramdrug

Citalopram 10-40 mg per day administered orally

Placebodrug

1/2-2 tablets per day with no intrinsic drug activity